Inter- and Intrapatient Mean Absorbed Dose Variation and Simplification of Dosimetric Workflow after PRRT Abstract #2998

Introduction: Post-PRRT dosimetry is not routinely performed, partly due to required multiple imaging time points. One time point imaging would reduce patient burden, and make dosimetry more applicable in the clinical settings.
Aim(s): To assess patient variation in mean absorbed dose and kinetics, to eventually estimate the cumulative activity using one imaging time point.
Materials and methods: Four post-therapy imaging time points of 10 patients treated with a total of 38 PRRT cycles were available for dosimetry. Coefficients of variation (CoV) were calculated for inter- and intrapatient mean absorbed dose variation. Target kinetics were used to calculate the true cumulative activity using all imaging time points after each cycle. The estimated cumulative activity was based on population average kinetics (using the first cycle of each patient or all 38 cycles) and target specific kinetics based from the first cycle.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors
Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Markus Galler
Authors: Galler M, Schatka I, Buch F, Bluemel S, ...
#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Minseok Suh
Authors: Suh M, Cheon G J, Lee D S, ...